Bispecific Anti-CD3/CD20 Formulation for Aggregation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bispecific antibodies targeting CD3 and CD20 are susceptible to degradation, aggregation, and instability under high-temperature conditions or shear stress, posing challenges for production, storage, and administration.
Innovation Solution
A liquid or lyophilized powder formulation of the bispecific anti-CD3/CD20 polypeptide complex using buffers like histidine salt, succinate, and citrate buffers, along with saccharides such as trehalose, and surfactants like polysorbate 80, to maintain stability and biological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bisspecific anti-CD3/CD20 polypeptide complex is used for therapy, then therapeutic effect is improved, but stability under high-temperature conditions or shear stress deteriorates
Solution Approach 1:
The patent applies parameter changes by optimizing formulation conditions including pH (5.0-7.5), temperature (2-8°C storage), concentration (0.1-50 mg/mL), and composition (buffers, excipients, surfactants) to achieve stable bispecific antibody formulations that maintain therapeutic efficacy while resisting degradation under various storage and transport conditions
Solution Approach 2:
The patent employs composite materials by creating complex formulations that combine bisspecific antibodies with multiple excipients including buffers (histidine, succinate, citrate), saccharides (trehalose, sucrose), amino acids (arginine, glycine, proline), and surfactants (polysorbate 80, poloxamer 188) to enhance stability while maintaining therapeutic function
2Reliability
If bisspecific antibody drugs are used, then therapeutic capability is improved, but susceptibility to degradation, aggregation or unwanted chemical modifications increases
Solution Approach 1:
The patent applies preliminary anti-action by incorporating stabilizing excipients and protective agents in the formulation that prevent degradation, aggregation, and chemical modifications before they can occur during storage and transport, thereby preserving therapeutic capability
Solution Approach 2:
The patent creates an inert environment through the use of stabilizing buffers and excipients that provide a protective chemical environment, preventing unwanted interactions between the bisspecific antibody and external factors that could cause degradation or aggregation
3Stability of the object's composition
If bisspecific polypeptide complex formulation is developed, then stability during storage is improved, but formulation complexity increases
Solution Approach 1:
The patent applies universality by selecting excipients that perform multiple functions simultaneously - for example, buffers that maintain pH stability while also acting as stabilizers, and saccharides that provide both structural support and protection against aggregation, thereby managing formulation complexity
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3B
AI summary
The present invention provides a novel bispecific anti-CD3/CD20 polypeptide complex formulation containing a first antigen-binding portion and a second antigen-binding portion. Specifically, the formulation comprises a liquid formulation and a lyophilized formulation.